These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17611378)

  • 21. Roles of infusional high-dose 5-fluorouracil with leucovorin in advanced colorectal cancer.
    Liu JH
    Clin Colorectal Cancer; 2004 Sep; 4(3):204-5. PubMed ID: 15377404
    [No Abstract]   [Full Text] [Related]  

  • 22. [Initial results of randomized studies of metastatic colorectal carcinoma urge careful and controlled use of CPT-11].
    Klautke G; Fietkau R
    Strahlenther Onkol; 2002 Mar; 178(3):163-4. PubMed ID: 11962194
    [No Abstract]   [Full Text] [Related]  

  • 23. Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer.
    Yao Y; Sun YJ; Zhao H; Guo YW; Lin F; Cai X; Tang XC; Tang LN; Zhang W
    Chin Med J (Engl); 2006 Nov; 119(21):1829-33. PubMed ID: 17097039
    [No Abstract]   [Full Text] [Related]  

  • 24. Randomized trial comparing the addition of oxaliplatin or irinotecan to high-dose leucovorin and 5-Fluorouracil intravenous bolus every two weeks in metastatic colorectal carcinoma: Southern Italy Cooperative Oncology Group 0103.
    Comella P
    Clin Colorectal Cancer; 2003 Nov; 3(3):186-9. PubMed ID: 14706179
    [No Abstract]   [Full Text] [Related]  

  • 25. [Chemotherapy of colorectal carcinoma].
    Lutz MP; Adler G
    Internist (Berl); 2001 Dec; 42(12):1567-8, 1571-6, 1578-82. PubMed ID: 11793596
    [No Abstract]   [Full Text] [Related]  

  • 26. Scheduling of fluorouracil: a forget-me-not in the jungle of doublets.
    Sobrero AF
    J Clin Oncol; 2004 Jan; 22(1):4-6. PubMed ID: 14665617
    [No Abstract]   [Full Text] [Related]  

  • 27. Sequential chemotherapy for colorectal cancer.
    Seymour M
    Lancet Oncol; 2011 Oct; 12(11):987-8. PubMed ID: 21903471
    [No Abstract]   [Full Text] [Related]  

  • 28. Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.
    Hwang JJ
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):26-34. PubMed ID: 15685831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic chemotherapy for metastatic colorectal cancer: reasons to combine.
    Calvo E
    Clin Colorectal Cancer; 2002 Nov; 2(3):170-2. PubMed ID: 12482333
    [No Abstract]   [Full Text] [Related]  

  • 30. [Chemotherapy for colorectal cancers].
    Lièvre A; Mitry E
    J Chir (Paris); 2003 Feb; 140(1):52-5. PubMed ID: 12709655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?
    Schmoll HJ; Sargent D
    Lancet; 2007 Jul; 370(9582):105-107. PubMed ID: 17630019
    [No Abstract]   [Full Text] [Related]  

  • 32. Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
    Punt CJ
    Ann Oncol; 2005 Jun; 16(6):845-6. PubMed ID: 15890668
    [No Abstract]   [Full Text] [Related]  

  • 33. Long-term outcome of unresectable metastatic colorectal cancer: does "adjuvant" chemotherapy play a role after resection?
    Power DG; Kemeny NE
    Ann Surg; 2009 Oct; 250(4):654-5; author reply 655. PubMed ID: 19730229
    [No Abstract]   [Full Text] [Related]  

  • 34. [Outpatient chemotherapy of an advanced or metastatic colorectal cancer].
    Sato T; Kokuba Y; Ozawa H; Hatate K; Nakamura T; Onosato W; Ihara A; Watanabe M
    Gan To Kagaku Ryoho; 2006 Dec; 33 Suppl 2():257-9. PubMed ID: 17469353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.
    Saam J; Critchfield GC; Hamilton SA; Roa BB; Wenstrup RJ; Kaldate RR
    Clin Colorectal Cancer; 2011 Sep; 10(3):203-6. PubMed ID: 21855044
    [No Abstract]   [Full Text] [Related]  

  • 36. Size matters. What can we learn from a small randomized trial?
    Saltz L
    Onkologie; 2007 Apr; 30(4):167. PubMed ID: 17469240
    [No Abstract]   [Full Text] [Related]  

  • 37. Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
    Garant A; Des Groseilliers S; Martin L; Ferland É; Vuong T
    Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):497-8. PubMed ID: 21576010
    [No Abstract]   [Full Text] [Related]  

  • 38. [Advances in the treatment of metastatic colorectal cancer with bevacizumab].
    Longo F; Mansueto G
    Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449
    [No Abstract]   [Full Text] [Related]  

  • 39. [Guidance and informed consent in colon cancer therapy].
    Akazawa S; Yamashina T; Murakami T; Nakazima T; Sakurai T
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():547-51. PubMed ID: 14574953
    [No Abstract]   [Full Text] [Related]  

  • 40. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX.
    Chang DZ; Abbruzzese JL
    Clin Adv Hematol Oncol; 2005 May; 3(5):400-4. PubMed ID: 16167013
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.